Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda Hands CEO Baton to Kim after 12-Year Weber Era
Takeda Pharmaceutical formally ushered in the Julie Kim era on June 24 after shareholders approved the transition of the CEO role from Christophe Weber — bringing to a close a 12-year chapter that transformed the company from a traditional Japanese…
To read the full story
Related Article
- Takeda’s FY2025 Sales Fall 1.7% on Vyvanse Generic Erosion
May 14, 2026
- Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
- Takeda to Nominate CEO-Elect Kim to Board at June AGM
March 27, 2026
- Takeda Unveils Annual 200 Billion Yen Cost Savings by FY2028
March 26, 2026
- Takeda Rejigs Structure Ahead of CEO Transition, Creates New International Unit
January 30, 2026
- Takeda Zeros in on US Successor Ahead of 2026 CEO Transition
June 26, 2025
- Julie Kim Tapped to Take Over Helm of Takeda in 2026
January 31, 2025
BUSINESS
- Takeda Hands CEO Baton to Kim after 12-Year Weber Era
June 24, 2026
- Regenxbio Clears Path to Resubmit Hunter Syndrome Gene Therapy
June 24, 2026
- Merck Biopharma Files Lurbinectedin for SCLC in Japan
June 24, 2026
- FRONTEO Joins Dementia Prevention Cohort Study with KIBIT AI
June 24, 2026
- Alfresa Invests in Digital Health Startup eMind
June 24, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…